Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

PURPOSE: Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evaluated the safety and activity of T-DXd in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Modi, Shanu, Park, Haeseong, Murthy, Rashmi K., Iwata, Hiroji, Tamura, Kenji, Tsurutani, Junji, Moreno-Aspitia, Alvaro, Doi, Toshihiko, Sagara, Yasuaki, Redfern, Charles, Krop, Ian E., Lee, Caleb, Fujisaki, Yoshihiko, Sugihara, Masahiro, Zhang, Lin, Shahidi, Javad, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280051/
https://www.ncbi.nlm.nih.gov/pubmed/32058843
http://dx.doi.org/10.1200/JCO.19.02318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280051/
https://www.ncbi.nlm.nih.gov/pubmed/32058843
http://dx.doi.org/10.1200/JCO.19.02318

Ejemplares similares